WNT2 and neoplasm: Recently, it was found that using WNT2 monoclonal antibody with PD-1 monoclonal antibody significantly restored intra-tumor anti-tumor T cell responses and improved anti-PD-1 efficacy in mouse OSCC and CRC homologous tumor models by increasing the number of active DCs (Huang et al., 2022a).